July 8, 2020

Menicon Co., Ltd.
President and CEO: Hidenari Tanaka
Securities Code: 7780
TSE, 1st section, NSE, 1st section
Contact:
Motonari Watanabe
Senior Executive Officer,
Corporate Management, CFO
Phone: +81-52-935-1646

Notice Regarding Wenzhou FocuSee Vision Care, a contact lens factory in China, is made our wholly-owned subsidiary

Menicon Co., Ltd. (Menicon) hereby announces that on June 23, 2020, it acquired all the shares of the Chinese contact lens manufacturing company and a consolidated subsidiary Wenzhou FocuSee Vision Care Technologies Co. Ltd. (FocuSee), and made it a wholly-owned subsidiary.
For details, please refer to the follows.

1. Overview of FocuSee
   Name: Wenzhou FocuSee Vision Care Technologies Co. Ltd.
   Representative: Ryuji Kano
   Location of headquarters: Wenzhou City, Zhejiang Province
   Establishment: 2003

2. Purpose and Outline
   FocuSee was established by the School of Ophthalmology & Optometry, Wenzhou Medical University, which has an extensive track record of research in the field of ophthalmology. FocuSee is among the three manufacturers whose manufacture of hard contact lenses has been approved by and registered with the National Medical Products Administration (NMPA)*. Menicon acquired a stake in the company in 2008 and began providing technical support. By acquiring 100% of FocuSee's shares, we will create the base for manufacturing gas permeable hard contact lenses and special contact lenses, and we will do our best to provide our lineup of new products in China at high quality, low cost and short delivery time to as many medical institutions and patients as possible in China.

*The National Medical Products Administration (NMPA): An organization similar to the Pharmaceuticals and Medical Devices Agency in Japan.

3. Outlook

Menicon forecasts that the agreement will have only a minimal effect on the Company's consolidated business results for the fiscal year ending Mar. 31 2021. Because FocuSee has been already our consolidated subsidiary.

End.

July 8, 2020
Menicon Co., Ltd.

Wenzhou FocuSee Vision Care, a contact lens factory in China, is made our wholly-owned subsidiary



Wenzhou FocuSee Vision Care relocated to Eye Valley,
Longwan District, Wenzhou Province

On Tuesday, June 23, 2020, Menicon Co., Ltd. acquired all the shares of the Chinese contact lens manufacturing company Wenzhou FocuSee Vision Care Technologies Co. Ltd. (hereinafter abbreviated as FocuSee) (address: Wenzhou City, Zhejiang Province; representative: Ryuji Kanoh), and made it a wholly-owned subsidiary.

FocuSee was established in 2003 by the School of Ophthalmology & Optometry, Wenzhou Medical University, which has an extensive track record of research in the field of ophthalmology. FocuSee is among the three manufacturers whose manufacture of hard contact lenses has been approved by and registered with the National Medical Products Administration (NMPA)*. Menicon acquired a stake in the company in 2008 and began providing technical support. FocuSee has thus far handled numerous national projects, and, in recognition of their high technological capabilities, the Chinese Government awarded them the status of “National High-tech Enterprise**” in

2014. The company currently sells, through agencies all over China, products such as SenSkyZ that uses Menicon Z, a high oxygen-permeable material that Menicon Group takes pride in.

At Menicon, we expect to see a further rise in patients requiring special lenses—our specialization—due to the increasing number of people with myopia and corneal irregular astigmatism in China. By acquiring 100% of FocuSee's shares, we will create the base for manufacturing gas permeable hard contact lenses and special contact lenses into which we plan to generously inject the production technologies that we have accumulated thus far. We will do our best to provide our lineup of new products in China at high quality, low cost and short delivery time to as many medical institutions and patients as possible in China.

*The National Medical Products Administration (NMPA): An organization similar to the Pharmaceuticals and Medical Devices Agency in Japan.
**National High-Tech Enterprise: China's national high-tech enterprises were recognized by the government as those corporations which, in the "national key development high-tech sector," continue to improve their R&D and technological achievements, and whose business activities form their intellectual property rights, which become the core of the corporation. Enterprises awarded this status are eligible to receive tax breaks and other incentives.

End